S1PR1 and multiple sclerosis: Sphingosine 1-phosphate receptor 1 (S1P1)1 modulators are emerging as a new class of drugs with potential therapeutic application in multiple sclerosis (15), and fingolimod is a nonselective sphingosine 1-phosphate (S1P) receptor modulator (16, –18, 21, 22).